Simple determination of urine cefazolin concentration in pediatric patients with urinary tract infections using high-performance liquid chromatography

被引:4
作者
Abe, Kurumi [1 ,2 ]
Momo, Kenji [2 ]
Abe, Yoshifusa [3 ]
Kanazawa, Takeru [3 ]
Karato, Ryo [3 ]
Tanaka, Katsumi [1 ,2 ]
Sasaki, Tadanori [4 ]
机构
[1] Showa Univ, Koto Toyosu Hosp, Dept Pharm, Tokyo, Japan
[2] Showa Univ, Dept Hosp Pharmaceut, Sch Pharm, Tokyo, Japan
[3] Showa Univ, Koto Toyosu Hosp, Childrens Med Ctr, Tokyo, Japan
[4] Showa Univ Hosp, Dept Pharm, Tokyo, Japan
关键词
cefazolin; HPLC; pediatric; urine concentration; UV; DRUG DELIVERY SYSTEM; PHARMACOKINETICS; MOXALACTAM; ASSAY;
D O I
10.1002/bmc.5495
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Recently, global health concerns regarding increasing multidrug resistance have arisen. This study aimed to develop a simple, inexpensive and rapid high-performance liquid chromatography-ultraviolet (HPLC-UV) method for determining urinary concentrations of a first-generation cephem antibiotic in pediatric patients with urinary tract infections (UTIs). HPLC-UV was used to analyze urinary cefazolin concentrations at a detection wavelength of 254 nm. The assay used contained 10-fold diluted urine with an internal standard (cephapirin). The standard calibration curve for cefazolin was linear in the concentration range of 31.25-500 mu g/ml (r(2) > 0.999). The retention times of cefazolin and the internal standard were 4.2 and 4.9 min, respectively. The within- and between-day coefficients of variation were in the concentration ranges 1.2-15.2 and 5.5-19.2%, respectively. The urinary cefazolin concentration of a pediatric patient with a UTI was 1,476.6 mu g/ml, which was over 700-fold higher than the minimum inhibitory concentration of cefazolin (<= 2 mu g/ml). The developed method is applicable to the confirmation of appropriate use for UTI treatment as therapeutic drug monitoring of cefazolin. Therefore, the findings of this study may contribute to the appropriate use of antibiotics to prevent antimicrobial resistance in pediatric patients with UTIs.
引用
收藏
页数:7
相关论文
共 26 条
[1]  
Abe Y, 2016, Glob Pediatr Health, V3, DOI [10.1177/2333794X15625297, DOI 10.1177/2333794X15625297]
[2]   Sensitive assay for the determination of cefazolin or ceftriaxone in plasma utilizing LC [J].
Al-Rawithi, S ;
Hussein, R ;
Raines, DA ;
AlShowaier, I ;
Kurdi, W .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 22 (02) :281-286
[3]  
[Anonymous], 2018, GUID IND BIOAN METH
[4]   Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery [J].
Asada, Mizuho ;
Nagata, Masashi ;
Mizuno, Tomohiro ;
Uchida, Tokujiro ;
Kurashima, Naoki ;
Takahashi, Hiromitsu ;
Makita, Koshi ;
Arai, Hirokuni ;
Echizen, Hirotoshi ;
Yasuhara, Masato .
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2018, 6 (06)
[5]   PHARMACOKINETICS OF DIBENZYLAMINE ADMINISTERED IN A SUSTAINED DRUG DELIVERY SYSTEM WITH CEFAZOLIN [J].
CALVO, MB ;
PEDRAZ, JL ;
DOMINGUEZGIL, A .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (09) :797-806
[6]   The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery [J].
Douglas, Alexandra ;
Altukroni, Mahdi ;
Udy, Andrew A. ;
Roberts, Michael S. ;
Taraporewalla, Kersi ;
Jenkins, Jason ;
Lipman, Jeffrey ;
Roberts, Jason A. .
BMC ANESTHESIOLOGY, 2011, 11
[7]  
Fuke Toshiya, 2010, Kansenshogaku Zasshi, V84, P269
[8]  
Irie S., 1999, ANTIBIOT CHEMOTHER, V15, P100
[9]  
Ishikawa Y., 1978, SHINRYO SHINYAKU, V15, P919
[10]  
JAID/JSC, 2019, WORK GROUP JAID JSC